Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
The Transcend CLL 004 Clinical Trial is looking for patients with relapsed or refractory CLL/SLL. The investigational treatment uses a “living drug” made up of our own immune cells, called T cells, that are genetically modified into chimeric antigen receptor (CAR) T cells called JCAR017 that are programmed to recognize and attack CLL. This is very similar to the JCAR014 that I received and worked so well for me. For more information and eligibility, click https://www.centerwatch.com/XYOO/, but remember CAR-T therapy is still experimental and not for everyone. Take a look at my CAR-T blog for the up and downsides of this revolutionary therapy.
Disclaimer: Please carefully review this or any clinical trial or therapy decision with your treatment team. The CLL Society wants you to be informed of all your treatment options but does not endorse any particular trial or therapy, including this one.
Related posts